[go: up one dir, main page]

MX2016011862A - Inhibidores de c5a para el tratamiento de la neumonia viral. - Google Patents

Inhibidores de c5a para el tratamiento de la neumonia viral.

Info

Publication number
MX2016011862A
MX2016011862A MX2016011862A MX2016011862A MX2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A
Authority
MX
Mexico
Prior art keywords
treatment
pneumonia
inhibitors
viral pneumonia
relates
Prior art date
Application number
MX2016011862A
Other languages
English (en)
Inventor
Guo Renfeng
Christoph Riedemann Niels
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50342223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016011862(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of MX2016011862A publication Critical patent/MX2016011862A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a inhibidores de C5a para uso en el tratamiento de la neumonía, especialmente de la neumonía viral. La invención también se refiere al uso de inhibidores de C5a en la preparación de una composición farmacéutica para el tratamiento de la neumonía, especialmente de la neumonía viral. Los inventores se refieren además a métodos para el tratamiento de la neumonía, especialmente de la neumonía viral, que comprenden la etapa de administrar una cantidad terapéutica de un inhibidor de C5a a un sujeto en necesidad del mismo.
MX2016011862A 2014-03-20 2015-03-20 Inhibidores de c5a para el tratamiento de la neumonia viral. MX2016011862A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14160947 2014-03-20
PCT/EP2015/055947 WO2015140304A1 (en) 2014-03-20 2015-03-20 Inhibitors of c5a for the treatment of viral pneumonia

Publications (1)

Publication Number Publication Date
MX2016011862A true MX2016011862A (es) 2016-12-05

Family

ID=50342223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011862A MX2016011862A (es) 2014-03-20 2015-03-20 Inhibidores de c5a para el tratamiento de la neumonia viral.

Country Status (15)

Country Link
US (2) US10227397B2 (es)
EP (1) EP3119802B1 (es)
JP (2) JP6718379B2 (es)
KR (1) KR20160127042A (es)
CN (2) CN106132982A (es)
AU (1) AU2015233380A1 (es)
BR (1) BR112016021629A2 (es)
CA (1) CA2940319A1 (es)
CL (1) CL2016002255A1 (es)
EA (1) EA201691481A1 (es)
IL (1) IL247364A0 (es)
MX (1) MX2016011862A (es)
PH (1) PH12016501830A1 (es)
SG (1) SG11201607740TA (es)
WO (1) WO2015140304A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132982A (zh) 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
SG10201914111XA (en) 2014-03-20 2020-03-30 Samumed Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
US20190127453A1 (en) 2016-06-07 2019-05-02 Novartis Ag An anti-c5 antibody dosing regimen
SG10202012243VA (en) 2016-06-14 2021-01-28 Regeneron Pharma Anti-c5 antibodies and uses thereof
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
CN111108118A (zh) * 2017-04-03 2020-05-05 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
JP7502865B2 (ja) * 2017-06-23 2024-06-19 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
CN120571008A (zh) 2017-12-13 2025-09-02 瑞泽恩制药公司 抗c5抗体组合及其用途
PH12022550167A1 (en) 2019-08-16 2023-05-08 Regeneron Pharma High concentration anti-c5 formulations
TWI834025B (zh) * 2020-03-06 2024-03-01 美商奥默羅斯公司 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
CN116390758A (zh) * 2020-03-27 2023-07-04 因弗拉克斯有限责任公司 用于治疗冠状病毒感染的C5a抑制剂
JP2023522208A (ja) * 2020-04-16 2023-05-29 アシスタンス ピュブリック－オピト ド パリ ウイルスによって引き起こされる補体媒介性障害を処置する方法
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
JP2024540086A (ja) 2021-10-28 2024-10-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ５をノックアウトするためのｃｒｉｓｐｒ／ｃａｓ関連方法及び組成物
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001301A (es) * 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
CN1642983A (zh) * 2002-01-25 2005-07-20 G2治疗有限公司 抗C5aR抗体及其应用
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
CA2785612C (en) * 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
PT2563813E (pt) * 2010-04-30 2015-11-26 Alexion Pharma Inc Anticorpos anti-c5a e métodos para utilização dos anticorpos
WO2011160083A1 (en) * 2010-06-17 2011-12-22 Trellis Bioscience, Inc. Antibodies useful in passive influenza immuization
CN106132982A (zh) 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂

Also Published As

Publication number Publication date
EA201691481A1 (ru) 2017-02-28
AU2015233380A1 (en) 2016-09-08
EP3119802A1 (en) 2017-01-25
JP2017514791A (ja) 2017-06-08
EP3119802B1 (en) 2019-12-04
SG11201607740TA (en) 2016-10-28
JP7041708B2 (ja) 2022-03-24
JP2020125324A (ja) 2020-08-20
CN106132982A (zh) 2016-11-16
US10227397B2 (en) 2019-03-12
US20170137499A1 (en) 2017-05-18
US20190202900A1 (en) 2019-07-04
IL247364A0 (en) 2016-11-30
WO2015140304A1 (en) 2015-09-24
US10858421B2 (en) 2020-12-08
BR112016021629A2 (pt) 2018-07-10
JP6718379B2 (ja) 2020-07-08
CL2016002255A1 (es) 2017-08-25
KR20160127042A (ko) 2016-11-02
CA2940319A1 (en) 2015-09-24
CN116785426A (zh) 2023-09-22
PH12016501830A1 (en) 2016-11-21

Similar Documents

Publication Publication Date Title
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
ZA202004557B (en) Modulatory polynucleotides
TW201613901A (en) New compounds
MY187540A (en) Compounds active towards bromodomains
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
PH12016500094A1 (en) Autotaxin inhibitors
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MY199091A (en) Therapeutic compounds
IN2014MU00303A (es)
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX370412B (es) Compuesto antimicotico.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2017000929A (es) Inhibidores de aldosterona sintasa.
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
IN2014MU00916A (es)
IN2014CH00840A (es)
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
IN2013MU03428A (es)